University of Medicine and Pharmacie Tg. Mureş International Congress for Students, Young Physicians and Pharmacists Marisiensis 2014 Author: Buzdugan.

Slides:



Advertisements
Similar presentations
Case 20 Thomas J. Giordano, M.D., Ph.D.. History A 54-year old man with a past medical history of goiter for approximately 4 years was followed by ultrasound.
Advertisements

Edoardo Pescarmona Dipartimento di Medicina Sperimentale
Lymphomas in the Mediastinum. Mediastinal Large B Cell Lymphoma.
60 y. o. Female. Tumour on the right upper arm
MANTLE CELL Lymphoma (WITH EMPHASIS ON THE gi TRACT)
Proposed WHO Classification of Lymphoid neoplasm
Is the BRAF V600E mutation useful as a predictor of preoperative risk in papillary thyroid cancer? The American Journal of Surgery.
Lymphoma Dr. Raid Jastania Dec By the end of this session you should be able to: –Discuss the basis of the classification of lymphomas –Know the.
Ji Young Lee, MD, PhD, David Marchetti, MD, M Steven Piver, MD Department of Obstetrics and Gynecology Sisters of Charity Hospital, Buffalo, NY The Clinical.
Pier Luigi Filosso, MD University of Torino, Department of Thoracic Surgery The Impact of Adjuvant Chemotherapy in Pulmonary Large Cell Neuroendocrine.
LYMPHOMA.
Lymphoma DR: Gehan Mohamed.
Non-Hodgkin’s lymphomas-definition and epidemiology
Genetic Alterations of TP53 Gene in Brain Astrocytic Tumours Methodology Θ Eighty-three brain tumor biopsies were collected and used in this study. Thirty.
O THER MALIGNANT LYMPHOPROLIFERATIVE DISORDERS The lymphomas and plasma cell problems.
(Relates to Chapter 31, “Nursing Management: Hematologic Problems,” in the textbook) Copyright © 2011, 2007 by Mosby, Inc., an affiliate of Elsevier Inc.
Edward Camacho Mina 1061 MD4 WINDSOR UNIVERSITY HODGKIN LYMPHOMA.
A Phase 2 Study of Brentuximab Vedotin in Patients with Relapsed or Refractory CD30-Positive Non-Hodgkin Lymphomas: Interim Results in Patients with DLBCL.
Kerrington Smith, M.D. CTOS Nov 14, 2008
LUNG ADENOCARCINOMAS. CLINICOPATHOLOGICAL STUDY WITH RESPECT TO THE UPCOMING NEW CLASSIFICATION AND EGFR-KRAS MUTATION ANALYSIS IMPLICATIONS. First author:
Unknown Primary Tumors: Newer Concepts and Approches “ 10 years experience of a Comprehensive Cancer Center” Valerio Ramazzotti S.C. Epidemiologia Roma.
Changes in Breast Cancer Reports After Second Opinion Dr. Vicente Marco Department of Pathology Hospital Quiron Barcelona. Spain.
University of Medicine and Pharmacie Tg. Mureş International Congress for Students, Young Physicians and Pharmacists Marisiensis 2014 Author: Buzdugan.
Clinical-pathological parameters in squamous cell carcinoma of the tongue Chairperson: Dr. Md. Harun-ar- Rashid Assistant Professor & Head Department of.
T-cell/histiocyte-rich large B cell lymphoma Monirath Hav, MD, PhD fellow Pathology Department Ghent University Hospital.
© Cancer Research UK 2005 Registered charity number Table One: Numbers and rates of new cases, non-Hodgkin lymphoma, UK, 2006 EnglandWalesScotlandN.IrelandUK.
First author: Roman Adina Co-author: Andone Sebastian
INCREASED EXPRESSION OF PROTEIN KINASE CK2  SUBUNIT IN HUMAN GASTRIC CARCINOMA Kai-Yuan Lin 1 and Yih-Huei Uen 1,2,3 1 Department of Medical Research,
XRCC1Arg194Trp gene polymorphism and risk of lymphoma in a Romanian population First author: Anda Ştefan Co-authors: Cristina Radu George Crauciuc Coordinators:
Myeloproliferative Disorders (MPDs)
First Author: Radu Cristina Co-Authors: Stefan Anda Tripon Florin Crauciuc George Coordinators: Banescu Claudia, MD Demian Smaranda, MD The importance.
Poster Title ABSTRACT #59 Cell cycle progression genes differentiate indolent from aggressive prostate cancer. Steven Stone 1 Jack Cuzick 2, Julia Reid.
بسم الله الرحمن الرحيم. Adult Hodgkin’s Lymphoma in the Eastern Part of Libya Dr. M.Mangoush, R. Nafo, S.Kardah, M.Letaiwish, S.Kardah, F.Bodabous, S.Ebkhatra.
P27 REGULATION IN PERIPHERAL T-CELL LYMPHOMA NOT OTHERWISE SPECIFIED Gazzola A, Agostinelli C, Righi S, Rossi M, Sista MT, Zinzani PL, Pileri SA, Piccaluga.
Correlation between post-PTCA resolution of ST segment and mortality in STEMI patients First author: Diana Opincariu Co-authors: Carmen Moldovan Daniel.
The 2008 WHO classification of lymphoid neoplasms and beyond: evolving concepts and practical applications by Elias Campo, Steven H. Swerdlow, Nancy L.
Dr Sam Ley CT2 ICM Dr Radha Sundaram Consultant ICM Royal Alexandra Hospital, Paisley, Scotland.
Lymphoma Rob Jones. Aim and learning outcomes Aim ◦ To revise the key points of lymphoma Learning outcomes ◦ Revise the basics of haemopoiesis ◦ Understand.
2010 Hematopoietic and Lymphoid Neoplasms
Future Directions in ALK Negative Anaplastic Large Cell Lymphoma
Clinicopathologic Features of EML4-ALK Mutant Lung Cancer Shaw AT et al. ASCO 2009; Abstract (Poster)
Thyroid Cancer Incidence in Massachusetts, Richard Knowlton, MS Annie MacMillan, MPH Massachusetts Cancer Registry Massachusetts Department of.
HANDOUT 3 RARITIES.
Annals of Oncology 23: 298–304, 2012 종양혈액내과 R4 김태영 / prof. 김시영.
The revised International Prognostic Index (R-IPI) is a better predictor of outcome than the standard IPI for patients with diffuse large B-cell lymphoma.
Asymptomatic lymphadenopathy Mediastinal mass Systemic symptoms Fever, Pruritus Other nonspecific symptoms and paraneoplastic syndromes Intra-abdominal.
CLINICAL ASPECT OF GRADING AND STAGING Hanggoro Tri Rinonce, MD, PhD Department of Anatomical Pathology Faculty of Medicine, Gadjah Mada University.
R2 김재민 / Prof. 정재헌 Journal conference 1.
Dodo Case 10 A 48 year old male initially presented with spinal cord compression and a paraspinal mass. He received local radiation therapy. Eight months.
by Elaine S. Jaffe, Nancy Lee Harris, Harald Stein, and Peter G
Critical Reviews in Oncology / Hematology
Woo Cheal Cho MD1, Fabiola Balarezo, MD1
THE IMPORTANCE OF STAGING AND PROGNOSTIC FACTORS IN CANCER CARE
An unusual type of primary breast lymphoma
CASE OF THE MONTH Dr Narender Tejwani Consultant ( Hematopathologist)
Comparison between Pathologic Characteristics of Her2 Negative and Positive Breast Cancer in a Single Cancer Center in Jordan DR Majdi A. Al Soudi, MD,
EXPRESSION OF ABERRANT p53 PROTEIN IN GASTRIC CANCER
Discussion & Conclusion Predictives of Meningioma Grading
Chronic immune activation in HIV associated Non Hodgkin lymphoma and the effect of antiretroviral therapy Brian Flepisi University of the Western Cape.
EMT inducing transcription factor SIP1: a predictive biomarker of colorectal cancer survival and recurrence? A Patel, R Sreekumar, R Bhome, KA Moutasim,
5th International Symposium October 22nd – 24th, Varese, Italy
Changes to the Hematopoietic and Lymphoid Neoplasm Coding Manual
The Frequency of Immunoglobulin Heavy Chain Gene and T-Cell Receptor γ-Chain Gene Rearrangements and Epstein-Barr Virus in ALK+ and ALK− Anaplastic Large.
T-cell NHL: US Perspective
Lymphomas Expressing ALK Fusion Protein(s) Other Than NPM-ALK
Peripheral T Cell Lymphoma Prognostic Factors
Brenton T. Tan, Roger A. Warnke, Daniel A. Arber 
Utilizing NGS-Data to Evaluate Anti-PD-1 Treatment
Outcomes in patients with PTCL
Presentation transcript:

University of Medicine and Pharmacie Tg. Mureş International Congress for Students, Young Physicians and Pharmacists Marisiensis 2014 Author: Buzdugan Dumitriţa Scientific coordinators: Conf. Dr. Mihai Turcu, Şef lucr. Dr. Ovidiu S. Cotoi

Introduction Peripheral T cell lymphoma (PTCL) is a type of lymphoproliferation of mature T cells (post thymic stage) Rare, aggressive, with poor outcome World Health Organization's classification, dating 2008, includes three subtypes of PTCL :

PTCL – Non otherwise specified PTCL – Angioimmunoblastic PTCL – Anaplastic ALK+ and ALK-

I PTCL – NOS (non otherwise specified) Positive at normal T cell markers but with a down regulation of CD5, CD7 Aberrant expression of CD20, CD79a and CD30 Histologically there are known three variants: Lennert Follicular T-zone

II PTCL - angioimmunoblastic Positive at T cell markers: CD2, 3, 5, TCR CD10, BCL-6, CXCL-13 positive – markers for T helper lymphocytes important proliferation at endothelial arborization level

III PTCL - anaplastic ALK + CD30, 2, 4, 5, 25 positive and partially positive at CD45 and CD45 RO There have not been observed antibodies for Epstein Barr virus ALK – CD30, 43 positive Loss of T cell markers

Material and method Retrospective descriptive study upon 29 patients diagnosed with PTCL between 2008 and 2013 diagnosed in the County Hospital of Tg. Mureş Clinical criteria: site of primary tumor Demographic criteria: age and gender Immunohistochemical criteria: presence of specific markers

Results  Demographic

  Types

 Histological: in all PTCLs developed in the lymph nodes their structure was totally modified by the neoplasm Results I PTCL developed in the lymph node in which the structure is completely modified, 2x, H.E. Source: Morphopathology Department’s Library of The County Hospital of Tg. Mures

II. Lymph Node 20x, H.E. Source: Morphopathology Department’s Library of County Hospital Tg. Mures III. Lymph Node 20x, H.E. Malignant mitotic cells. Source: Morphopathology Department’s Library of County Hospital Tg. Mures

IV. PTCL developed in the spleen 2x, 10x, 20x H.E. Source: Morphopathology Department’s Library of County Hospital Tg. Mures 4x

V. PTCL developed in the spleen 10x, 20x. H.E. Source: Morphopathology Department’s Library of County Hospital Tg. Mures 20x

 Immunohistochemistry

Discussions High incidence in men, fifth decade of life [1] [5] PTCL-NOS is the most common type of PTCLs with a 83% incidence (while in other studies it has shown a 25-30% incidence) [2][3]

Imprecise differentiation between PTCL- NOS and PTCL-anaplastic ALK- (both CD30 positive)  high importance of genetic studies [4] Significant decreasing incidence of PTCLs from 2008 to 2013 in this center of study

Conclusions The latest update of the WHO classification has useful criteria for PTCL diagnostic The information obtained in this study is in accordance with that from the specialized literature: high frequency in middle aged male with T cell markers expression maintained – CD3 Further studies about immunofenotyping must be correlated with genetic studies for a better treatment outcome

Limitations of the study: Retrospective design Restricted to a single center’s patients Small number of cases

Questions ?

References Bettina Bisig, Aurelien de Reynies, Christophe Bonnet, et al: CD30-positive peripheral T-cell lymphomas share molecular and phenotypic features. The Hematology Journal, 98: , 2013 Brenton T. Tan, Roger A. Warnke, Daniel A. Arber: The frequency of B- and T-Cell Gene Rearrangements and Epstein-Barr Virus in T-Cell Lymphomas. The Journal of Molecular Diagnostics, 8: , 2006 Harry L. Ioachim, L. Jeffery Medeiros: Ioachim’s Lymph Node Pathology, 4 th edition Julie M. Vose, Neumann M., Mildred E. Harris: International T- cell and Natural Killer/T-cell Lymphoma Study: Pathology findings and Clinical Outcomes. Journal of Clinical Oncology, 26: , 2008 [1]

Laurence de Leval, Philippe Gaulard: CD30+ lymphoproliferative disorders. The Hematology Journal, 35 : , 2010 [4] Mihai Turcu, Angela Borda, Vasile Bud: Diagnosticul microscopic al leziunilor nodulului limfatic, ed. Mureş 1999 Philip Went, Claudio Agostinelli, Andrea Gallamini, et al. : Marker Expression in Peripheral T-cell Lymphoma: A proposed Clinical-Pathologic Prognostic Score. Journal of Clinical Oncology, 24: , 2006 [2] Pier Paolo Piccaluga, Claudio Agostinelli, Anna Gazzola, et al.: Prognostic Markers in Peripheral T-cell Lymphoma. Current Hematologic Malignancy Reports, 5: , 2010 [3]

Steven H. Swerdlow, Elias Campo, Nancy Lee Haris, et al: WHO Classification of Tumors of Haematopoietic and Lymphoid Tissues, 4 th edition. International Agency for Research on Cancer, Lyon, 2008 [5]

Thank you for your attention !